Pirtobrutinib for Richter's Transformation - Dr. William Wierda ASH 2023

Pirtobrutinib for Richter's Transformation - Dr. William Wierda ASH 2023Подробнее

Improving upon the standard of care for patients with Richter’s transformationПодробнее

Pirtobrutinib for Richter’s Transformation - Dr. Nirav Shah ASH 2022Подробнее

SIOP 2024: EDUCATIONAL: NOVEL THERAPEUTIC APPROACHES TO HIGH RISK B-ALLПодробнее

Insights into the BRUIN CLL-322 trialПодробнее

Subcutaneous Epcoritamab for Richter's Syndrome - Dr. Arnon Kater ASH 2022Подробнее

The pharmacokinetics of pirtobrutinibПодробнее

Novel treatment regimens under investigation for Richter's transformationПодробнее

The use of pirtobrutinib in Richter's transformation: data from the BRUIN trialПодробнее

Genomic evolution and resistance to pirtobrutinib in CLL: insights from the BRUIN studyПодробнее

MURANO trial: duvelisib plus venetoclax in R/R CLL, SLL and Richter’s SyndromeПодробнее

Richter’s syndrome and its impact on CLL patientsПодробнее

ASH 2024: Dr. Rachid Baz Discusses a Personalized Daratumumab-Based Response Adapted TherapyПодробнее

CLL: Treatment for BTKi ProgressorsПодробнее

Updates from studies using CLL mouse modelsПодробнее

Evolution of Chronic Lymphocytic Leukemia (CLL) to Richter's Syndrome - Dr. Stephan StilgenbauerПодробнее

Outcomes of Richter's Syndrome in CLL Patients Treated W/ Chemotherapy With or Without BTK InhibitorПодробнее

BRUIN CLL-322: pirtobrutinib plus VR vs VR alone in R/R CLLПодробнее

Treating Richter's Syndrome with Venetoclax, Atezolizumab, and Obinutuzumab – ICML 2023Подробнее